title: [Coasting: a response to excessive ovarian stimulation].
abstract: The ovarian hyperstimulation treatment increases results of in vitro fertilization. However, the risk of ovarian hyperstimulation syndrome must be carefully evaluated for each patient. An excessive response increases complication and cancellation rates. Coasting could be applied when an excessive response occurred. This method requires stopping gonadotropin administration while GnRH agonist is continued. When the estradiol rate decreases, the hCG administration is allowed. In the literature, results shows adequate pregnancy rates, between 26 and 64%. It seems oocyte quality was not spoiled. However, coasting does not eliminate definitively the risk of ovarian hyperstimulation syndrome. Coasting method could be a safe and efficient method to treat an excessive ovarian response during in vitro fertilization protocol. Pregnancy rates seem to be preserved.
authors.affiliation: Service de gynécologie obstétrique, CHU A. de Villeneuve, faculté de médecine de Montpellier-Nîmes, France.
authors.forename: H
authors.initials: H
authors.lastname: Dechaud
authors.forename: T
authors.initials: T
authors.lastname: Anahory
authors.forename: N
authors.initials: N
authors.lastname: Aligier
authors.forename: F
authors.initials: F
authors.lastname: Arnal
authors.forename: C
authors.initials: C
authors.lastname: Humeau
authors.forename: B
authors.initials: B
authors.lastname: Hédon
mesh_terms: D006063:Chorionic Gonadotropin / Q000494:pharmacology / Q000627:therapeutic use*; D002985:Clinical Protocols; D016903:Drug Monitoring / Q000379:methods*; D004624:Embryo Transfer; D004958:Estradiol / Q000097:blood*; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D005496:Follicular Atresia / Q000187:drug effects; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008596:Menotropins / Q000494:pharmacology / Q000627:therapeutic use*; D016471:Ovarian Hyperstimulation Syndrome / Q000209:etiology* / Q000517:prevention & control*; D010062:Ovulation Induction / Q000009:adverse effects* / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome; D012307:Risk Factors; D014463:Ultrasonography
chemical_list: D006063:Chorionic Gonadotropin; D005300:Fertility Agents, Female; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D008596:Menotropins